Dana-Farber Cancer Institute is committed to providing expert, compassionate care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases.
New Product & Tech activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
BMS CELMoD Drug Shows Positive Phase III Results
Akeso and INOVIO partner for glioblastoma treatment
Sign up to see the full signal feed
How Dana-Farber Cancer Institute's international expansion compares to its competitors
Dana-Farber Cancer InstituteYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Dana-Farber Cancer InstituteYou | 1 | 0 | +100% | 1 | 11 |
Senior Research Administrator
View postingBoston, MA · 3w ago
Infection Preventionist
View postingBoston, MA · 4d ago
Professor
View postingBoston, MA · 4d ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Ascentage Pharma presented clinical data on APG-2575 for R/R MM at ASH, showing strong efficacy and safety in combination therapy.
Trastuzumab deruxtecan (T-DXd) shows impressive activity against brain metastases in HER2-positive advanced breast cancer patients, offering a new treatment option.
Dana-Farber Cancer Institute's trial shows personalized cancer vaccine effective for stage III/IV clear cell renal carcinoma patients, with all nine participants remaining cancer-free after treatment.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Dana-Farber Cancer Institute's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
